Showing results (101-110 of 413) with videos related to
Sort By:
Pageof 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) miceS Visonneau, A Cesano, M H Torosian, et al.European Cytokine Network|November 27, 1998
Positive and negative regulation of interleukin-12 gene expressionX Ma, H Riemann, G Gri, et al.Current Topics in Microbiology and Immunology|December 6, 2005
Dendritic cell-NK cell cross-talk: regulation and physiopathologyL Zitvogel, M Terme, C Borg, et al.The Journal of Experimental Medicine|May 1, 1985
Inhibition of bone marrow colony formation by human natural killer cells and by natural killer cell-derived colony-inhibiting activityG Degliantoni, B Perussia, L Mangoni, et al.Journal of Virology|December 1, 1995
The in vivo antiviral activity of interleukin-12 is mediated by gamma interferonL Ozmen, M Aguet, G Trinchieri, et al.The Journal of Biological Chemistry|April 16, 1998
Synergistic regulation of the human interleukin-12 p40 promoter by NFkappaB and Ets transcription factors in Epstein-Barr virus-transformed B cells and macrophagesG Gri, D Savio, G Trinchieri, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1984
Phorbol esters enhance spontaneous cytotoxicity of human lymphocytes, abrogate Fc receptor expression, and inhibit antibody-dependent lymphocyte-mediated cytotoxicityG Trinchieri, T O'Brien, M Shade, et al.The Journal of Experimental Medicine|July 1, 1986
Gamma interferon and lymphotoxin, released by activated T cells, synergize to inhibit granulocyte/monocyte colony formationM Murphy, R Loudon, M Kobayashi, et al.The Journal of Biological Chemistry|April 18, 1997
Identification and characterization of a novel Ets-2-related nuclear complex implicated in the activation of the human interleukin-12 p40 gene promoterX Ma, M Neurath, G Gri, et al.Cancer Gene Therapy|October 10, 2009
Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant BaxH Garg, R Salcedo, G Trinchieri, et al.Pageof 42